新一代人工智慧模型旨在加速藥物研發
New AI Model Designed to Speed Up Drug Discovery
2026年，醫學領域正在發生劇烈的變化。
In 2026, the landscape of medicine is changing rapidly.
傳統的藥物研發流程過去往往耗時超過十年且耗資數十億美元，如今正受到人工智慧的顛覆。
The traditional process of drug discovery, which often took over a decade and cost billions, is being transformed by Artificial Intelligence.
科學家不再依賴緩慢的物理實驗錯誤試驗，而是利用AI在電腦上模擬並設計潛在的藥物。
Rather than relying on slow, physical trial-and-error, scientists now use AI to simulate and design potential medicines on computers.
像AlphaFold這類的工具讓研究人員能理解蛋白質結構，而生成式模型則能從零開始創造出類似藥物的新分子。
Tools like AlphaFold allow researchers to understand protein structures, while generative models create new drug-like molecules from scratch.
關鍵在於，AI並非為了取代人類專家。
Crucially, AI is not meant to replace human experts.
相反地，它扮演著強大的合作夥伴，協助研究團隊在藥物進入實驗室之前，就預測其在人體內的運作表現。
Instead, it acts as a powerful partner, helping teams predict how a drug will behave in the body long before it reaches a lab.
儘管資料隱私及高品質資訊需求等挑戰仍然存在，但像FDA這類的監管機構正日益整合這些技術。
Although challenges like data privacy and the need for high-quality information persist, regulatory bodies like the FDA are increasingly integrating these technologies.
透過結合人類的專業知識與運算速度，製藥產業正邁向更有效率的未來。
By combining human expertise with computational speed, the pharmaceutical industry is moving toward a more efficient future.
